For decades, researchers have worked to create drugs that teach the immune system to kill cancer cells the way traditional ...

As few as one in ten people survive pancreatic cancer five years after their diagnosis — making it the most difficult cancer to survive. The survival rate five years after diagnosis is 6-14%, but ...

Recent positive lab confirmation of Smart mRNA functionality is a tremendous milestone for the Company. This marks a ...

Clinical studies indicate that the mRNA vaccine may help treat pancreatic cancer, one of the deadliest cancers, reports ...

Clinical studies suggest that the mRNA vaccine may play a role in treating pancreatic cancer, identified as one of the most ...

Several ASX-listed healthcare companies with low market caps are making strides in tackling cancer,  a leading cause of death ...

Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer ...

The study developed a noninvasive detection method based on serum protease activity, leveraging the increased protease activity in the peripheral blood of patients with PDAC. Researchers screened a ...

Pancreatic cancer is the 10th deadliest form of cancer in the United States, according to the National Cancer Institute.

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three ...

A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease ...

The mRNA vaccine works by targeting genetic mutations found in pancreatic cancer, alerting the immune system to recognize and ...